Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says
Executive Summary
Early launch data from Genentech's Avastin indicate the oncologic will not affect Xeloda sales, Roche Worldwide Pharmaceuticals Head William Burns said
You may also be interested in...
Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care – Roche
Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained
Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care – Roche
Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained
Genentech Avastin Early Sales Data Suggest Broad Use In Colorectal Cancer
Genentech is receiving public reimbursement for use of Avastin in both first-line and relapsed/refractory metastatic colorectal cancer, the company told investors April 8